Das Purkayastha

1.9k total citations
58 papers, 1.4k citations indexed

About

Das Purkayastha is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Das Purkayastha has authored 58 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Cardiology and Cardiovascular Medicine, 18 papers in Endocrinology, Diabetes and Metabolism and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Das Purkayastha's work include Blood Pressure and Hypertension Studies (31 papers), Hormonal Regulation and Hypertension (16 papers) and Heart Rate Variability and Autonomic Control (12 papers). Das Purkayastha is often cited by papers focused on Blood Pressure and Hypertension Studies (31 papers), Hormonal Regulation and Hypertension (16 papers) and Heart Rate Variability and Autonomic Control (12 papers). Das Purkayastha collaborates with scholars based in United States, Canada and Switzerland. Das Purkayastha's co-authors include Yves Lacourcière, Rita Samuel, Michael R. Zile, Sharon L. Mulvagh, William Daley, J. Malcolm O. Arnold, John E. Gerich, Philip Raskin, Gerard P. Aurigemma and Rajesh Janardhanan and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Das Purkayastha

57 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Das Purkayastha United States	20	623	303	273	269	220	58	1.4k
Jean‐François Abgrall France	21	785 1.3×	296 1.0×	821 3.0×	137 0.5×	100 0.5×	34	2.1k
Tetsuya Mitarai Japan	17	375 0.6×	291 1.0×	73 0.3×	168 0.6×	62 0.3×	54	1.3k
Roberto Marchioli Italy	23	699 1.1×	142 0.5×	378 1.4×	205 0.8×	64 0.3×	40	2.1k
Daniela Seidinger Austria	24	831 1.3×	145 0.5×	217 0.8×	185 0.7×	225 1.0×	42	1.8k
Angela M. Carter United Kingdom	20	445 0.7×	222 0.7×	502 1.8×	430 1.6×	42 0.2×	30	1.5k
B. Bottasso Italy	21	283 0.5×	151 0.5×	677 2.5×	175 0.7×	39 0.2×	38	1.5k
Geneviève Le Calvez France	8	604 1.0×	105 0.3×	148 0.5×	49 0.2×	23 0.1×	14	905
Ulrich Neyer Austria	21	246 0.4×	259 0.9×	181 0.7×	182 0.7×	52 0.2×	32	2.1k
David J. Moliterno United States	32	2.5k 4.0×	180 0.6×	365 1.3×	263 1.0×	62 0.3×	100	3.4k
Femke Waanders Netherlands	20	500 0.8×	285 0.9×	98 0.4×	280 1.0×	37 0.2×	47	1.6k

Countries citing papers authored by Das Purkayastha

Since Specialization

Citations

This map shows the geographic impact of Das Purkayastha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Das Purkayastha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Das Purkayastha more than expected).

Fields of papers citing papers by Das Purkayastha

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Das Purkayastha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Das Purkayastha. The network helps show where Das Purkayastha may publish in the future.

Co-authorship network of co-authors of Das Purkayastha

This figure shows the co-authorship network connecting the top 25 collaborators of Das Purkayastha. A scholar is included among the top collaborators of Das Purkayastha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Das Purkayastha. Das Purkayastha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bardia, Aditya, Sara A. Hurvitz, Angela DeMichele, et al.. (2021). Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). Clinical Cancer Research. 27(15). 4177–4185. 80 indexed citations

Maziarz, Richard T., Mark J. Levis, Mrinal M. Patnaik, et al.. (2020). Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplantation. 56(5). 1180–1189. 100 indexed citations

Maziarz, Richard T., Mrinal M. Patnaik, Bart L. Scott, et al.. (2018). Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML. Blood. 132(Supplement 1). 662–662. 51 indexed citations

Moulder, Stacy, Denise A. Yardley, Gail S. Wright, et al.. (2018). Abstract CT107: Ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Efficacy and safety results from phase II of the TRINITI-1 study. Cancer Research. 78(13_Supplement). CT107–CT107. 3 indexed citations

Ritchie, Ellen K., Rosalind Catchatourian, Rebecca B. Klisovic, et al.. (2017). Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib. Blood. 130. 2875–2875. 7 indexed citations

Barrios, Carlos H., Martin E. Blackstein, Jean‐Yves Blay, et al.. (2015). The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours. European Journal of Cancer. 51(16). 2423–2433. 25 indexed citations

Cushman, William C., Daniel Duprez, Howard Weintraub, et al.. (2012). Home and clinic blood pressure responses in elderly individuals with systolic hypertension. Journal of the American Society of Hypertension. 6(3). 210–218. 3 indexed citations

Giles, Thomas D., Thomas R. Alessi, Das Purkayastha, & Dion Zappe. (2012). Comparative Efficacy of Aliskiren/Valsartan vs Valsartan in Nocturnal Dipper and Nondipper Hypertensive Patients: A Pooled Analysis. Journal of Clinical Hypertension. 14(5). 299–306. 4 indexed citations

Ferdinand, Keith C., et al.. (2012). Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with Stage 2 hypertension. Journal of the American Society of Hypertension. 6(3). 219–227. 6 indexed citations

10.

Weintraub, Howard, Daniel Duprez, William C. Cushman, et al.. (2012). Antihypertensive Response to Thiazide Diuretic or Angiotensin Receptor Blocker in Elderly Hypertensives Is Not Influenced by Pretreatment Plasma Renin Activity. Cardiovascular Drugs and Therapy. 26(2). 145–155. 8 indexed citations

11.

Whaley‐Connell, Adam, et al.. (2011). Central Pressure and Biomarker Responses to Renin Inhibition with Hydrochlorothiazide and Ramipril in Obese Hypertensives: The ATTAIN Study. Cardiorenal Medicine. 1(1). 53–66. 8 indexed citations

12.

Ofili, Elizabeth, Suzanne Oparil, Thomas D. Giles, et al.. (2011). Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups. Journal of the American Society of Hypertension. 5(4). 249–258. 6 indexed citations

13.

Giles, Thomas D., Suzanne Oparil, Elizabeth Ofili, et al.. (2011). The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. Blood Pressure Monitoring. 16(2). 87–95. 14 indexed citations

14.

Ferdinand, Keith C., James L. Pool, Richard E. Weitzman, Das Purkayastha, & Raymond R. Townsend. (2010). RESPONSES TO ALISKIREN/HCTZ VERSUS AMLODIPINE ON PERIPHERAL AND CENTRAL BLOOD PRESSURE IN AFRICAN AMERICAN PATIENTS WITH STAGE 2 HYPERTENSION. Journal of the American College of Cardiology. 55(10). A61.E586–A61.E586. 3 indexed citations

15.

Sowers, James R., Leopoldo Raij, Brent M. Egan, et al.. (2010). Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives. Journal of Hypertension. 28(8). 1761–1769. 27 indexed citations

16.

Lacourcière, Yves, Jackson T. Wright, Rita Samuel, et al.. (2009). Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study. Blood Pressure Monitoring. 14(3). 112–120. 15 indexed citations

17.

Solomon, Scott D., Rajesh Janardhanan, Anil Verma, et al.. (2007). Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. The Lancet. 369(9579). 2079–2087. 254 indexed citations

18.

Neutel, Joel M., David H.G. Smith, Michael A. Weber, et al.. (2006). Efficacy of Combination Therapy With Amlodipine Besylate/Benazepril Hydrochloride for Lowering Systolic Blood Pressure in Stage 2 Hypertension. The American Journal of Geriatric Cardiology. 15(3). 142–150. 7 indexed citations

19.

Janardhanan, Rajesh, William Daley, Tasneem Z. Naqvi, et al.. (2006). Rationale and design: The VALsartan In Diastolic Dysfunction (VALIDD) Trial: Evolving the management of diastolic dysfunction in hypertension. American Heart Journal. 152(2). 246–252. 22 indexed citations

20.

Mohler, Emile R., David Herrington, Pamela Ouyang, et al.. (2006). A Randomized, Double‐Blind Trial Comparing the Effects of Amlodipine Besylate/Benazepril HCl vs Amlodipine on Endothelial Function and Blood Pressure. Journal of Clinical Hypertension. 8(10). 692–698. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact